Innovate Biopharmaceuticals Inc (NASDAQ:INNT) shares traded up 4.8% during mid-day trading on Friday . The company traded as high as $6.38 and last traded at $5.52. 35,380 shares were traded during trading, a decline of 96% from the average session volume of 972,741 shares. The stock had previously closed at $5.80.
A number of research analysts have recently issued reports on the company. Seaport Global Securities reaffirmed a “buy” rating on shares of Innovate Biopharmaceuticals in a research note on Wednesday, June 13th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Innovate Biopharmaceuticals in a research note on Wednesday, July 25th. Finally, ValuEngine cut Innovate Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, July 16th.
Innovate Biopharmaceuticals (NASDAQ:INNT) last posted its earnings results on Wednesday, May 16th. The company reported ($0.76) earnings per share (EPS) for the quarter. Innovate Biopharmaceuticals had a negative return on equity of 1,923.83% and a negative net margin of 218.08%. equities research analysts predict that Innovate Biopharmaceuticals Inc will post -1.32 earnings per share for the current fiscal year.
Innovate Biopharmaceuticals Company Profile
Innovate Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase 2b clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase 1 clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease.
Further Reading: Outstanding Shares
Receive News & Ratings for Innovate Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovate Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.